|  | Sample type | ELN risk group | Karyotype | Molecular alterations | % CD 34 positive cells |
---|---|---|---|---|---|---|
1 | bm | Healthy donor | - | 46,XY | - | NA |
2 | pb | AML patient | Fav | 46:xy | NPM1, FLT3 normal, CEBPA mut | 60% |
3 | bm | AML patient | Fav | 46,XX,t(15;17)(q22;q11)[24]/46,XX[1] 96% of altered methaphases | PML/RARα | CD34- |
4 | pb | AML patient | Int-I | 46,XY | NPM1 mut (mut A), FLT3 mut | CD34- |
5 | bm | AML patient | Int-I | 46,XY | NPM1and FLT3 normal | 82% |
6 | pb | AML patient | Int-II | 47,XY,+19[13]/47,XY,+del(1)(p13)[3]/46,XY[9] 64% of altered methaphases | NPM1 mut (Mut A), FLT3 mut | 52% |
7 | pb | AML patient | Int-II | 46,XX,del(1)(p33)[6]/46,XX[1] 86% of altered methaphases | NPM1 mut (mut A), FLT3 normal | CD34- |
8 | pb | AML patient | Adv | Complex karyotype 100% of altered methaphases | - | 78% |
9 | bm | AML patient | Adv | Complex karyotype 100% of altered methaphases | NPM1and FLT3 normal | 89% |
10 | NB4 | AML Cell line | - | - | Â | CD34- |
11 | ML2 | AML Cell line | - | - | PML/RARα | CD34- |
12 | ME-1 | AML Cell line | - | - | - | 100% |
13 | pb | Healthy donor | - | 46,XY | - | NA |
14 | bm | AML patient | Fav | 46,XY | NPM1 mut (MUT K) FLT3 normal | 27% |
15 | pb | AML patient | Fav | 46,XY | Â | CD34- |
16 | bm | AML patient | Fav | 46,XX | NPM1 Mut (Mut C), FLT3 norm | CD34- |
17 | pb | AML patient | Int-I | 46,XY | NPM1 mut (Mut A),FLT3 mut | 48% |
18 | apheresis | AML patient | Int-I | 46,XY | NPM1 mut (Mut A),FLT3 mut | 83% |
19 | pb | AML patient | Int-I | 46,XX | NPM1 mut (Mut B), FLT3 mut | 10% |
20 | bm | AML patient | Int-I | 46,XY | NPM1 norm, FLT3 mut | CD34- |
21 | pb | AML patient | Int-II | 46,XX | FLT3 mut (+75 ITD), NPM1 normal | CD34- |
22 | pb | Healthy donor | - | 46,XY | - | NA |
23 | pb | AML patient | Fav | 46,XY | NPM1 and FLT3 normal | CD34- |
24 | pb | AML patient | Fav | 46,XX | NPM1and FLT3 normal | CD34- |
25 | bm | AML patient | Int-I | 46,XX | FLT3 mut (+75 ITD), NPM1 norm | 22% |
26 | pb | AMLpatient | Int-I | 46,XY | FLT3 mut, NPM1 norm | 40% |
27 | pb | AML patient | Int-I | 46,XX | NPM1and FLT3 normal | 72% |
28 | pb | AML patient | Int-I | 46,XY | NPM1 mut (mut A), FLT3 mut | CD34- |
29 | pb | AML patient | Int-I | 46,XX | NPM1and FLT3 normal | 33% |
30 | pb | AML patient | Int-II | 46,XX,del(1)(p33)[6]/46,XX[1] 86% of altered methaphases | NPM1 mut (mut A), FLT3 normal | CD34- |
31 | bm | AMLpatient | Int-II | 46,XY,t(12;17)(p13;q21)[9]/46,XY[1] 90% of altered methaphases | FLT3 mut (+8 ITD), NPM1 norm | 87% |
32 | pb | AML patient | adv | 46,XY,der(8)t(8;?)(p11;?)[20] 100% of altered methaphases | NPM1and FLT3 normal | 89% |
33 | pb | AML patient | adv | Complex karyotype 100% of altered methaphases | NA | 78% |
34 | pb | Healthy donor | - | 46,XY | - | NA |
35 | bm | AML patient | Int-II | 46,XY,der(8)t(8;?)(p11;?)[20] 100% of altered methaphases | NPM1and FLT3 normal | 76% |
36 | pb | AML patient | Int-II | NA | NA | 90% |
37 | bm | AML patient | Int-II | NA | NA | 95% |
38 | pb | AML patient | Adv | NA | NA | CD34- |